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The interaction between intercellular adhesion molecules (ICAM) and the integrin
leukocyte function-associated antigen-1 (LFA-1) is crucial for the regulation of several 
physiological and pathophysiological processes like cell-mediated elimination of tumor 
or virus infected cells, cancer metastasis, or inflammatory and autoimmune processes. 
Using purified proteins it was reported a species restriction for the interaction of ICAM-1 
and LFA-1, being mouse ICAM-1 able to interact with human LFA-1 but not human
ICAM-1 with mouse LFA-1. However, in vivo results employing tumor cells transfected 
with human ICAM-1 suggest that functionally mouse LFA-1 can recognize human ICAM-
1. In order to clarify the interspecies cross-reactivity of the ICAM-1/LFA-1 interaction, 
we have performed functional studies analyzing the ability of human soluble ICAM-1
and human/mouse LFA-1 derived peptides to inhibit cell aggregation and adhesion as 
well as cell-mediated cytotoxicity in both mouse and human systems. In parallel, the 
affinity of the interaction between mouse LFA-1-derived peptides and human ICAM-1 
was determined by calorimetry assays. According to the results obtained, it seems that 
human ICAM-1 is able to interact with mouse LFA-1 on intact cells, which should be 
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Adhesion molecules are glycoproteins expressed on cell surfaces, where they mediate the contact 
between cell–cell, cell–extracellular matrix, and cell–pathogen. They are essential for physiological 
and pathological processes like embryonic development, wound healing, maintenance of tissue 
architecture, regulation of immune cell responses, migration of inflammatory cells into inflamed 
tissues, autoimmune diseases, and tumor metastasis (1, 2). Among the many molecules that regulate 
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these processes, the interaction between the members of the 
intercellular adhesion molecule (ICAM) family and the integrin 
leukocyte function-associated antigen-1 (LFA-1, also known as 
CD11a/CD18) is especially relevant, ICAM-1 being the most 
extensively studied and best characterized member of ICAMs.
Intercellular adhesion molecule-1 is a type I transmembrane 
cell-surface protein, belonging to the immunoglobulin super-
family, with a molecular weight of 80–120  kDa depending on 
the level of glycosylation. The extracellular portion of ICAM-1 
consists of 453 mainly hydrophobic amino acids, which form five 
immunoglobulin (Ig)-like domains. The extracellular region is 
attached to a single hydrophobic transmembrane region and a 
short cytoplasmic tail (3). ICAM-1 is the receptor for different 
human viruses like rhinovirus (4) and coxsackievirus A21 as well 
as for the malarial parasite Plasmodium falciparum (5) as well as 
different members of the integrin family like Mac-1 (6) and LFA-1 
(7–10). Among them, the interaction with LFA-1 is the most 
critical step that mediates immune cell migration, activation, and 
target cell recognition.
Intercellular adhesion molecule-1 is mainly expressed as a 
dimer on the cell surface and dimerization appears to enhance 
binding to LFA-1 (11). Nevertheless, each individual ICAM-1 
monomer is fully competent to bind LFA-1 and dimerization 
seems to be dispensable to form a complete LFA-1-binding site 
(12). Although ICAM-1 is usually anchored to the membrane, 
a soluble ICAM-1 molecule (sICAM-1) has been identified in 
serum. sICAM-1 is presented in serum from healthy humans at 
concentrations between 100 and 450 ng/ml (13) and increased 
levels of sICAM-1 have been found in serum from patients with 
cardiovascular and inflammatory diseases as well as during 
cancer metastasis (14, 15).
LFA-1 is a heterodimeric glycoprotein comprising a αL 
(CD11a, 180 kDa) and β2 (CD18, 95 kDa) subunits that are non-
covalently linked. Both domains have a complex structure that 
includes large extracellular domains, single-pass transmembrane 
segments, and short intracellular tails (16). The α subunit of 
LFA-1 (αL) contains an N-terminal stretch of 200 amino acids, 
the inserted (I) or A domain, that is crucial for the ligand-binding 
specificity (17). A metal ion-dependent adhesion site (MIDAS) is 
located in the upper face of the I-domain (18). ICAM-1 interacts 
with LFA-1 through the binding of its first Ig-domain (D1) with 
the MIDAS within the I-(inserted) domain at the top of the 
N-terminus of αL subunit of LFA-1 (19). The ICAM-1/LFA-1 
interaction is facilitated by magnesium and manganese divalent 
cations, assorted with five amino acids of MIDAS in LFA-1 and 
glutamate in domain 1 of ICAM-1 (20).
Interaction of LFA-1 in lymphocytes with ICAM-1 in target 
cells critically regulates all steps involved in the immune response 
including homing of lymphocytes, monocytes, and granulocytes 
during the inflammatory responses, Ag presentation, T helper 
and B lymphocyte responses, and T and natural killer (NK) 
cell-mediated killing (21, 22). In addition, it has been involved in 
several pathologies like metastasis of cancer cells or cardiovascu-
lar and autoimmune diseases.
Humanized mice are widely used as in vivo models to study 
the molecular basis of immune-related disorders as well as the 
efficacy of potential drugs (23). In these mice, the native gene of 
interest is replaced by its human homolog or the immune system 
is eliminated and reconstituted with its human counterpart. In 
addition, these mice can be used to enhance the engraftment of 
human cancer cells allowing in  vivo studies of cancer progres-
sion and treatment. Here, a major obstacle to analyze human cell 
function, either healthy or transformed, and disease is the lack 
of species cross-reactivity of many growth factors, cytokines, or 
ligands required for development, survival, and function of the 
human grafted tissue/cells. Most of the cell adhesion molecules 
involved in leukocyte function are conserved across species. 
However, some of them like CD2 differ in tissue distribution and 
ligands (24, 25). LFA-I and ICAM-1 are well conserved across 
species including tissue distribution, ligands, and function 
(26–28). However, using purified cell-free models, it has been 
described that mouse ICAM-1 binds human LFA-1, but human 
ICAM-1 does not bind mouse LFA-1 (29). In contrast, other 
groups have shown that in vivo control of cancer development 
by mouse immune system is enhanced by expression of human 
ICAM-1 (30–32). Later, it was reported that murine LAK cells 
kill more efficiently mouse tumor cells transfected with human 
ICAM-1 than parental non-transfected cells (33). These results 
suggest a functional binding of human ICAM-1 to mouse LFA-1.
As indicated, homing and effector function of immune cells 
as well as cancer metastasis are critically regulated by LFA-1/
ICAM-1 interaction and, thus, clarifying the species cross-
reactivity of these molecules is crucial to support the utility of 
humanized mice in immune-related pathologies and cancer and 
to understand the results thereof. Here, we provide the functional 
experimental evidence showing that human ICAM-1 is able to 
interact with mouse LFA-1 during immune cell adhesion and cell 
cytotoxicity.
eXPeriMenTal PrOceDUres
icaM-1 chimeras and lFa-1-Derived 
Peptides
The synthetic first two domains of ICAM-1 alone (D1D2) or 
linked with human IgG1 Fc region (D1D2Fc) were expressed in 
Escherichia coli and purified by single step column refolding as 
described (34). We have previously shown that the affinity of the 
interaction of human D1D2Fc with human LFA-1 is similar to a 
chimera formed by the five extracellular domains of ICAM-1, 
D1D5Fc (35). Mouse and human Fc chimeras containing the five 
extracellular domains of ICAM-1 (D1D5Fc) were purchased in 
R&D systems.
Human and mouse LFA-1-derived peptides (human: 
CD11a237–261; mouse: CD11a235–259) were purchased from GenScript 
(Piscataway, USA) without any modification. The sequences of 
CD11a237–261 and CD11a235–259 are ITDGEATDSGNIDAAKDII 
RYIIGI and ITDGEASDKGNISAAHDITRYIIGI, respectively, 
and have been previously characterized in basis of its ability to 
block ICAM-1/LFA-1 interaction (36).
Mouse strains
Mice (C57BL/6J) between 5 and 7 weeks of age were used. These 
mice were maintained and bred in pathogen-free conditions in 
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the animal facility of the Center for Agriculture Research and 
Technology (CITA) of the Government of Aragón. Mice were 
maintained on a 12 h light–dark cycle. Each cage contained aspen 
woodchip bedding (Capsumlab) and nesting material (shredded 
paper), and food (Harlan Laboratories) and tap water were pro-
vided ad libitum.
All procedures were approved by the Ethic Committee for 
Animal Experiments from CITA. The care and use of animals 
were performed accordingly with the Spanish Policy for Animal 
Protection RD53/2013, which meets the European Union 
Directive 2010/63 on the protection of animals used for experi-
mental and other scientific purposes.
isothermal Titration calorimetry (iTc)
The ability of the human chimera D1D2Fc to interact with a 
peptide derived from its natural ligand LFA-1 in mouse was 
analyzed by ITC on a VP-ITC calorimeter (MicroCal) at 25°C 
as indicated previously (34). Briefly, 2.2  ml of a 12-µM solu-
tion of D1D2Fc and 0.5  ml of a 150-µM solution of peptide 
were prepared in PBS and degassed. Each assay consisted of a 
series of 28 injections of peptide solution of 10  µl each (with 
a 4-µl first injection) at 400 s intervals under constant stirring 
(459  rpm). The thermal power required to keep the cell at a 
constant temperature is measured, so that it provides the heat 
associated with each ligand injection after integrating the signal 
over time. The thermodynamic parameters of protein–peptide 
interactions (affinity, enthalpy, and entropy changes) as well as 
the stoichiometry were estimated by using nonlinear regression 
analysis. Data were analyzed using the software developed and 
implemented in Origin 7.0 (OriginLab).
analysis of icaM-1 and lFa-1  
interaction by Flow cytometry
The ability of human D1D2Fc and mouse and human D1D5Fc to 
recognize LFA-1 on mouse cells was analyzed by flow cytometry 
in the mouse thymic lymphoma cell line EL4. EL4 cells were 
incubated with different concentrations of human D1D2Fc, mouse 
and human D1D5Fc and human IgG1 control at 4°C for 45 min, 
washed twice with FACS buffer (PBS, 5% FCS, 0.1% NaN3), and 
then incubated with PE-conjugated goat anti-human IgG (Fcγ 
fragment specific; Jackson ImmunoResearch). After a washing 
step with FACS buffer, cells were analyzed by FACS using a FACS 
Calibur with CellQuest Pro software (BD). As control cells were 
incubated with an antibody against mouse CD11a (LFA-1) before 
adding human D1D2Fc.
human and Mouse Macrophage 
Differentiation
Monocytes were isolated from human peripheral blood mono-
nuclear cells (PBMCs), obtained from healthy donors (Blood 
and Tissue Bank of Aragon; approved by the CEICA, number: 
C.I.PI11/006) by density gradient centrifugation using Ficoll-
Paque (GE healthcare). PBMCs were resuspended at a concen-
tration of 2.5  ×  106  cells/ml in RPMI medium supplemented 
with 1% heat-inactivated human AB serum (Sigma). Cells 
were cultured in a Petri dish for 2 h at 37°C 5% CO2. Then cells 
were carefully washed twice with PBS, and RPMI medium sup-
plemented with 10% FBS, 2 mM l-glutamine, and antibiotics 
(penicillin 100 U/ml, streptomycin 100 µg/ml) (complete RPMI 
medium) was added and cells were further incubated for 2 h at 
37°C 5% CO2. Cells were washed again with PBS and complete 
RPMI medium supplemented with GM-CSF (Invitrogen) 
at a concentration of 0.1  ng/ml was added. Cell culture was 
maintained for 6  days until monocytes are differentiated into 
macrophages. Macrophage differentiation was confirmed by 
microscopic evaluation under light microscope and by immu-
nophenotypical characterization using the following antibodies 
from BD Pharmingen: HLA-DR-PE, CD14-FITC, ICAM-1-
FITC, and LFA-1-APC.
Mouse macrophages were differentiated from mouse bone 
marrow as previously described (37). Briefly, bone marrow 
cells isolated from mouse femur were cultured in DMEM 10% 
FBS, 5% horse serum, and 30% supernatant of L929 cell culture 
as a source of M-CSF at a density of 106/cm2 for 7–8  days. 
Macrophage differentiation was analyzed in the same way as 
human macrophages but using CD11b-APC and CD11c-PE 
(BD) antibodies.
cell adhesion assays
Freshly isolated monocytes or differentiated macrophages were 
washed twice with PBS and incubated with trypsin (PAN Bio-
tech) for 30 min at 37°C 5% CO2. After that, cells were scraped 
gently from the plate and resuspended at a final concentration 
of 106 cells/ml in complete RPMI medium. Subsequently, 105 
macrophages and 5 × 105 monocytes were added to each well 
and incubated with several concentrations of human D1D2, 
D1D2Fc, D1D5Fc, mouse D1D5Fc, control human IgG1 20 µg or 
lovastatin 100 µM at 37°C 5% CO2 overnight. Next day, every 
well was washed twice with PBS, complete RPMI medium 
was added and the number or adherent remaining cells was 
quantified by a MTT colorimetric test (38). In some experi-
ments, plates previously coated with human and mouse D1D5Fc 
were used. To coat the plates 5 µg of D1D5Fc in 100 µl of PBS 
was incubated overnight at 4°C and subsequently plates were 
washed with PBS and blocked with 1% BSA in PBS for 2 h at 
room temperature.
nK cell-Mediated cytotoxicity
The effect of human and mouse peptides derived from LFA-1 
on ICAM-1/LFA-1 dependent cell–cell contact was analyzed 
by performing a cell cytotoxicity assay using human primary 
NK  cells and the NK  cell sensitive human leukemia K562. 
Primary activated human NK cells were generated by culturing 
PBMCs with mitomycin C inactivated R69 cells for 5 days and 
enriched by MACS using anti-CD56 antibodies as previously 
described (39). Cell cytotoxicity induced by NK cells on K562 
was analyzed by flow cytometry as previously described (39). 
Briefly, K562 cells were preincubated with medium alone, in the 
presence of 250 µM of human and mouse peptides from LFA-1 or 
D1D2 (15 µg) for 45 min at 37°C. Then, NK cells were added at 3:1 
effector:target cell ratio and incubated for 4 h at 37°C, 5% CO2. 
Subsequently, phosphatidylserine exposure and 7-AAD uptake 
were analyzed by FACS using the annexin-V/7-AAD kit from 
FigUre 1 | Interaction of LFA-1 peptide with D1D2Fc by isothermal titration 
calorimetry. Purified D1D2Fc (12 µM) was titrated with a peptide derived from 
the binding site of mouse LFA-1 (CD11a235–259; 150 µM). The assay was 
performed in PBS buffer at 25°C. The nonlinear regression analysis done as 
described in Section “Experimental Procedures” provided a dissociation 
constant of 70 nM.
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Immunostep. As a control, the cells were incubated alone with 
the inhibitors to evaluate their possible toxicity, which was not 
significant in any case.
cD8+ T cell-Mediated cytotoxicity
To check whether the human chimeras of ICAM-1 and human 
and mouse peptides from LFA-1 were able to recognize their 
counterpart in mouse cells, a cytotoxicity assay with lymphocytic 
choriomeningitis virus (LCMV)-specific CD8+ T cells gener-
ated in vivo and EL4 cells as targets as previously described (40) 
was carried out. Mice were inoculated intraperitoneally (i.p.) 
with 105 plaque-forming units LCMV–WE in 200 µl. At day 8 
post-infection, mice were sacrificed by cervical dislocation, the 
spleens were removed, splenocytes were isolated, and CD8 cell 
fraction was enriched by MACS, using anti-CD8-MicroBeads 
(Miltenyi Biotec). Subsequently, CD8 cells were resuspended 
in RPMI medium 5% decomplemented FBS and preincubated 
in the presence of several concentrations of human D1D2, 
D1D2Fc, mouse D1D5Fc, 250 µM of human and mouse LFA-1 
derived peptides, human IgG1 15 µg and lovastatin 100 µM for 
45 min at 37°C 5% CO2. EL4 cells were previously incubated 
for 2 h at 37°C 5% CO2 with 1 µM of the immunodominant 
peptide of LCMV, KAVYNFATM (gp33, NeoMPS). Then, CD8 
cells and EL4 target cells were incubated at ratio effector:target 
10:1 in 96-well plate conical bottom for 4 h at 37°C 5% CO2. 
Subsequently, phosphatidylserine exposure and 7-AAD uptake 
were analyzed by FACS using the annexin-V/7-AAD kit from 
Immunostep. As a control, EL4 cells and CD8 lymphocytes 
were incubated in the absence of gp33. In addition, in both 
cases, the cells were incubated alone with the inhibitors to 
evaluate their possible toxicity, which was not significant in 
any case.
B cell aggregation assay
The ability of human and mouse peptides from LFA-1 and human 
ICAM-1 to inhibit cell homotypic aggregation was analyzed by 
using mouse B cells. To obtain these cells, mice were sacrificed 
by cervical dislocation, the spleens were removed, and spleno-
cytes were isolated and resuspended in RPMI 10% FBS at a final 
concentration of 106 cells/ml. Cells were treated with 10 µg/ml 
PHA and 1 µg/ml ionomycin to activate LFA-1 and incubated at 
37°C 5% CO2 overnight in flat bottom 96-well plates (105 cells) 
in the presence of peptides from LFA-1 and c-Myc (control) 
250  µM, D1D2, D1D2Fc, and human IgG1 10  µg, EGTA 1  mM 
and lovastatin 100 µM. A qualitative aggregation assay was car-
ried out as described (36, 41) with a slight modification. Briefly, 
positive control stimulated cell samples were arbitrarily assigned 
a clumping index of 10 and lovastatin samples an index of 1. 
Test samples were ranked from 1 to 10 based upon degree of 
clumping relative to stimulated and lovastatin-treated samples. 
Results were verified by a blind independent rating performed 
by a second observer.
statistic analysis
Statistical analysis was performed using GraphPad Prism soft-
ware (GraphPad, San Diego, CA, USA) by two-way analysis of 
variance, followed by Bonferroni’s posttest.
resUlTs anD DiscUssiOn
interaction between human icaM-1 and 
Mouse Derived lFa-1 Peptides by iTc
In a previous work, we have shown that purified human 
recombinant ICAM-1 was able to interact with peptides derived 
from human LFA-1 (34). In order to test whether mouse LFA-1 
contained sequences that are able to recognize human ICAM-1, 
we have now analyzed by ITC the interaction between human 
ICAM-1 and a peptide derived from mouse LFA-1. This peptide 
contains the sequence of mouse LFA-1 corresponding to the pep-
tide of human LFA-1 that showed the highest affinity for human 
ICAM-1 (34).
As shown in Figure 1, the curvature of the binding isotherm 
implies a high affinity for D1D2Fc (KD = 70 nM) similar to the one 
observed previously with a peptide derived from human LFA-1 
(34). The complex formation was net exothermic as would be 
expected for a reaction in which specific intermolecular interac-
tions are established. Besides, if there were no interaction, there 
would not be any signal. This value was obtained by fitting to 
the binding isotherm a 1:n interaction model, which assumes a 
single type of binding sites. This result indicates that mouse LFA-1 
contains sequences that could interact with human ICAM-1 
and suggests that mouse LFA-1 could potentially bind human 
ICAM-1.
Binding of human icaM-1 with cell-
associated Mouse lFa-1
Isothermal titration calorimetry experiments suggest that human 
ICAM-1 is able to recognize a specific sequence derived from αI-
domain of the mouse integrin LFA-1 corresponding to the area of 
attachment to ICAM-1. However, although mouse LFA-1 derived 
short peptides have a high sequence homology in their counter-
partner in human and human ICAM-1 is capable of recognizing 
FigUre 2 | Analysis of D1D2Fc binding to LFA-1 in EL4 cells by flow cytometry. (a) Different amounts of D1D2Fc (0.1, 1, and 10 µg) or human IgG1 control (10 µg) 
were incubated with EL4 cells. After washing out non-bound proteins, cells were incubated with PE-conjugated goat anti-human IgG Fcγ Ab and analyzed by flow 
cytometry. As a control EL4 cells were pretreated with a mouse LFA-1 blocking antibody (anti LFA-1) before incubating with 10 µg of D1D2Fc. Histograms show a 
representative experiment. Values in the graph are represented as mean ± SEM of two independent experiments performed by duplicate. Statistical analysis was 
performed with two-way analysis of variance with Bonferroni’s posttest by comparing IgG with D1D2Fc. *p < 0.05; **p < 0.01. (B) Different amounts of mouse or 
human D1D5Fc (mICAM, hICAM; 0.1 and 5 µg) or human IgG1 control (10 µg) were incubated with EL4 cells. After washing out non-bound proteins, cells were 
incubated with PE-conjugated goat anti-human IgG Fcγ Ab and analyzed by flow cytometry. Histograms show a representative experiment.
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them, these linear amino acid sequences do not completely mimic 
the interaction among proteins containing a three-dimensional 
spatial structure. Thus, to prove that human ICAM-1 is capable 
of interacting with mouse LFA-1, we have analyzed the ability of 
the purified protein to bind the native form of LFA-1 expressed 
on the plasma membrane of mouse lymphoid cells. To this aim, 
we tested the interaction of D1D2Fc and LFA-1 in the mouse T cell 
line EL4 which express high levels of LFA-1 (data not shown) by 
flow cytometry (Figure 2A).
As shown in Figure 2A, the percentage of positive cells increases 
as it increases the amount of ICAM-1 chimera added, indica-
ting that human ICAM-1 is able to recognize and bind to mouse 
LFA-1 in compare with the negative control IgG. Incubation 
cells with a mouse antiCD11a (LFA-1) antibody blocked binding 
of the chimera.
To analyze the binding affinity of human ICAM-1 to mouse 
LFA-1, we compared the binding of mouse D1D5Fc and human 
D1D5Fc to EL4 cells. As shown in Figure 2B, both human and 
mouse ICAM-1 bound to EL4 cells, although in this case binding 
of human ICAM-1 was higher than binding of mouse ICAM-1.
To further evaluate and confirm that human ICAM-1 was 
able to interact with mouse LFA-1 in other cell types, we ana-
lyzed the ability of human ICAM-1 (D1D2Fc and D1D2) to block 
B cell aggregation by using a homotypic cell aggregation assay. 
Homotypic B cell aggregation is mostly due to ICAM-1/LFA-1 
interaction and this assay is widely used to analyze the affinity of 
LFA-1 and/or ICAM-1 ligands (7).
Fresh mouse B cells were obtained from splenocytes and stim-
ulated with PHA and ionomycin to induce homotypic adhesion. 
The images of cell aggregation assay are shown in Figure  3A, 
a–i. The results were quantified by establishing a clumping index 
that represents the degree of cell aggregation, which reflects the 
inhibition efficiency (Figure 3B). Cell aggregation was ranked by 
a clumping index from 1 to 10 based on the degree of aggregation 
FigUre 3 | Effect of human (ICAM-1) on the aggregation of mouse spleen cells. (a) Splenocytes isolated from mice were non treated (a) or activated with PHA 
(b–i) as described in Section “Experimental Procedures” and further incubated overnight with (b) medium; (c) IgG1; (d) c-Myc peptide; (e) EGTA; (f) lovastatin; (g) 
D1D2; (h) D1D2Fc; (i) mouse LFA-1 peptide CD11a235–259. Images were taken with an optical microscope (original magnification, 10×). Representative images from 
two independent experiments with similar results are shown. (B) The graph represents the rate of agglutination depending on the inhibitory effect on ICAM-1/
LFA-1 interaction. Cells stimulated with PHA and ionomycin, which served as a positive control, were arbitrarily assigned agglutination index 10, which represents 
a percentage of aggregation between 90 and 100%. Homotypic aggregation was classified from 1 to 10 depending on the degree of aggregation relative to cells 
stimulated. The result was verified by a second independent observer. Values are presented as mean ± SEM of two separate experiments performed by 
duplicate. Statistical analysis was performed using two-way analysis of variance with Bonferroni’s posttest comparing with c-Myc peptide control. *p < 0.05; 
***p < 0.001.
FigUre 4 | Inhibition of natural killer (NK) cell-mediated cytotoxicity by 
human intercellular adhesion molecule-1. Human NK cells isolated from 
healthy donors were activated and enriched by MACS as described in 
Section “Experimental Procedures” and labeled with the fluorescent probe 
CFSE. Subsequently they were incubated with K562 cells at effector:target 
(e:t) ratio 3:1 for 4 h in the presence or absence of human D1D2 or mouse 
LFA-1 peptide CD11a235–259 (250 µM), human LFA-1 peptide CD11a237–261 
(250 µM), and c-Myc peptide as control. Cell death was analyzed by 
measuring translocation of PS by flow cytometry in the negative population 
for CFSE as described in experimental procedures. Values are presented as 
mean ± SEM of two independent experiments performed by duplicate. 
Statistical analysis was performed using two-way analysis of variance with 
Bonferroni’s posttest comparing with c-Myc control. *p < 0.05; ***p < 0.001.
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in comparison with the stimulated cells (positive control, clump-
ing index = 10).
As expected, non-stimulated fresh B  cells did not aggregate 
in culture (Figure 3A, a). In contrast, cell aggregates were clearly 
visible in cultures after stimulation (Figure 3A, b). As controls, 
the cation chelator EGTA and the drug lovastatin (Figure 3A), 
which have been described to specifically block ICAM-1/LFA-1 
interaction without affecting other adhesion molecules such 
a Mac-1 or VLA-4 (42, 43), were able to inhibit completely the 
aggregation, while human IgG1 and a peptide derived from 
c-Myc (Figure 3A, c,d) did not present any effect. Besides, incu-
bation cells with a mouse antiCD11a (LFA-1) antibody blocked 
aggregation (data not shown). Human ICAM-1 (Figure 3A, g,h) 
significantly inhibited adhesion at concentration of 10 µg con-
firming that, as in the case of T cells, human ICAM-1 interacts 
with mouse LFA-1 in B cells. The mouse LFA-1 derived peptide 
(Figure 3A, i) completely blocked B cell aggregation confirming 
that this process was dependent on ICAM-1/LFA-1 interaction.
Our data using intact mouse cell expressing LFA-1 contrast 
with a previous work indicating that human ICAM-1 did not bind 
to mouse LFA-1 (29). Two explanations could account for these 
a priori contradictory results: (i) the previous work was performed 
FigUre 5 | Inhibition of cytotoxic CD8+ T cell-mediated cytotoxicity. (a) CD8+ cells were isolated by MACS from mice previously infected with lymphocytic 
choriomeningitis virus as described in Section “Experimental Procedures” and labeled with the fluorescent probe CTG. Subsequently they were incubated with EL4 
cells previously labeled with gp33 viral peptide at a e:t ratio 10:1 for 4 h in the presence or absence of different concentrations of human D1D2 and D1D2Fc, mouse 
LFA-1 peptide CD11a235–259, C-Myc 250 µM, IgG 15 µg, and lovastatin 100 µM. Cell death was analyzed by measuring translocation of PS by flow cytometry in the 
negative population CTG as described in experimental procedures. Values are presented as mean ± SEM of three independent experiments performed by duplicate. 
Statistical analysis was performed using two-way analysis of variance with Bonferroni’s posttest compared to the control IgG1 and c-Myc peptide for protein and the 
peptide, respectively. *p < 0.05; ***p < 0.001. (B) The same experiment as in (a) was performed but employing mouse intercellular adhesion molecule-1 (mICAM, 
D1D5Fc).
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using purified proteins and was not confirmed in intact cells or 
(ii) human ICAM-1 is binding to other integrins in EL4 or B cells 
like Mac-1. However, this is discarded since Mac-1 would bind to 
domain 3 in ICAM-1 and the proteins used here only consist of 
the first two domains. Thus, our results suggest that the interac-
tion between human ICAM-1 and mouse LFA-1 in intact cells is 
different from that observed using purified proteins. Our data are 
in line with previous works suggesting that mouse LFA-1 interact 
with target cells expressing human ICAM-1 (30–32).
Blocking of cell-Mediated cytotoxicity
As above mentioned, it has been previously reported that 
elimination of target cells by mouse cytotoxic lymphocytes is 
enhanced by overexpression of human ICAM suggesting that 
mouse LFA-1 is interacting with human ICAM-1 (33). Upon 
recognition of target cells, cytolytic leukocytes, NK, and mouse 
cytotoxic CD8+ T (Tc) cells, adhere to target cells before anti-
gen recognition takes place (44), and these cells might utilize 
regulated changes in adhesion to control immune recognition 
events (45). The main adhesion molecule that plays a key role 
in the interaction with target cells is ICAM-1. The interac-
tion of ICAM-1, expressed on tumor target cells, with LFA-1, 
expressed on the membrane of NK cells and Tc cell, modulates 
the formation and signaling of the immunological synapse and 
the subsequent elimination of the target cell (46).
First of all, we analyzed if the mouse LFA-1 derived peptide was 
able to block human NK cells mediated cytotoxicity on human 
K562 leukemic cells. As shown in Figure 4, this peptide was able 
to significantly inhibit cell death induced by human NK cells on 
the human leukemia cell line K562. This finding indicates that the 
peptide from mouse LFA-1 binds to human ICAM-1 in K562 cells 
preventing its interaction with LFA-1 on NK cells. As expected, 
a peptide derived from human LFA-1 as well as purified human 
ICAM-1 (D1D2) blocked NK cell-mediated cell death confirming 
the participation of ICAM-1/LFA-1 interaction in this process. 
Here, we only analyzed the effect of D1D2 to avoid a potential 
antibody dependent cell cytotoxicity effect when employing 
D1D2Fc quimera.
FigUre 6 | LFA-1 is involved in human macrophage adhesion. (a) Human monocytes were differentiated for 6 days in the presence of GM-CSF as indicated in 
Section “Experimental Procedures.” Representative images from cell cultures are shown (original magnification, 20×). (B) Macrophage phenotype was analyzed by 
flow cytometry testing the expression of HL-DR, CD14, CD54, and CD11a. A representative dot plot is shown. Numbers correspond to percentage of cells in each 
quadrant (c). Monocytes and macrophages were incubated at different concentrations of human D1D2 and D1D2Fc, human IgG1 20 µg and lovastatin 100 µM at 
37°C overnight. Subsequently, every well was washed twice with PBS to remove non-adherent cells and quantification of cell adhesion was carried out by MTT as 
described in Section “Experimental Procedures.” Values are presented as mean ± SEM of three independent experiments performed by duplicate. Statistical 
analysis was performed using two-way analysis of variance with Bonferroni’s posttest comparing with IgG1 control. ***p < 0.001.
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Next, we employed mouse Tc cells to analyze the effect of 
human purified ICAM-1 on its cytotoxic function. We have 
tested if human purified ICAM-1 was able to block cell death 
induced by LCM virus-specific Tc cells on mouse EL4 cells that 
express high levels of ICAM-1 (data not shown). As shown in 
Figure  5A, incubation with increasing amounts of human 
ICAM-1 completely blocked cell death induced by mouse Tc cells 
on LCMV gp33 antigen pulsed EL4 cells indicating that human 
ICAM-1 is interacting with mouse Tc cell-associated LFA-1 
and preventing its binding to ICAM-1 on EL4 target cells. The 
peptide from mouse LFA-1 was also able to inhibit cytotoxicity 
confirming the implication of ICAM-1/LFA-1 interaction in this 
process. As additional controls, lovastatin and mouse ICAM-1 
(D1D5Fc) inhibited cell death induced by Tc cells confirming the 
importance of ICAM-1 and LFA-1 during cell death induced by 
Tc cells. Mouse D1D5Fc (B) and human D1D2 and D1D2Fc (A) 
similarly prevented cell death induced by Tc cells indicating a 
similar affinity of human and mouse ICAM-1 to mouse LFA-1 in 
this model. In both cases, human NK cells and mouse Tc cells, the 
effect of the peptides was less pronounced than that of ICAM-1, 
which maybe explained due to a reduced capacity to block the 
interaction between ICAM-1 and LFA-1 by a short peptide in 
contrast to full ICAM-1.
Our results help to explain the previous observations in which 
expression of human ICAM-1 in mouse cancer cells favored its 
elimination in vitro and in vivo mediated by mouse immune cells 
including NK cells (30–33). These results suggested that mouse 
LFA-1 interacts with human ICAM-1. Here, we have confirmed 
this suggestion and shown that human ICAM-1 efficiently binds 
to mouse LFA-1 also in cytotoxic cells, preventing its function 
during cell-mediated elimination of target cells.
Blocking of Monocyte/Macrophage  
cell adhesion
The growth of adherent cells such as monocytes or macrophages 
requires signals not only from growth factor receptors but also 
from integrins (47). Integrins have two basic roles: to mediate 
adhesion and signaling (48, 49). Indeed, it has been described 
that LFA-1 is one of the most critical molecules involved in mono-
cyte/macrophage adhesion (49). To further proof that human 
ICAM-1 is able to bind mouse LFA-1, we decided to analyze this 
binding in another type of leukocytes, the macrophages. Thus, 
we analyzed the ability of human ICAM-1 (D1D2 and D1D2Fc) 
to block adhesion of mouse macrophages to plastic surfaces. 
As control, human monocytes and macrophages were used.
FigUre 7 | Human intercellular adhesion molecule (ICAM)-1 blocks LFA-1-mediated mouse macrophage cell adhesion. (a) Mouse macrophages were differentiated 
from bone marrow cells as described in Section “Experimental Procedures.” Representative images from cell cultures are shown (original magnification, 20×).  
(B) Macrophage phenotype was analyzed by flow cytometry testing the expression CD11b and CD11c. A representative dot plot is shown. Numbers correspond  
to percentage of cells in each quadrant. (c) Macrophages were incubated at different concentrations of human D1D2 and D1D2Fc, human IgG1 20 µg and lovastatin 
100 µM at 37°C overnight. Subsequently, every well was washed twice with PBS to remove non-adherent cells and quantification of cell adhesion was carried out 
by MTT as described in Section “Experimental Procedures.” (D,e) The same experiment as in C was performed but using plates previously coated with 5 µg of 
mouse or human ICAM-1 (mICAM and hICAM; D1D5Fc) as indicated. (D) % of cell adhesion in wells coated with human IgG, mouse D1D5Fc (mICAM) or human 
D1D5Fc (hICAM). (e) Effect of human D1D2 and anti-mouse LFA-1 on macrophage cell adhesion to mouse D1D5Fc (mICAM) or human D1D5Fc (hICAM)-coated 
plates. Values are presented as mean ± SEM of two separate experiments performed by duplicate. Statistical analysis was performed using two-way analysis  
of variance with Bonferroni’s posttest comparing with IgG1 control. *p < 0.05; ***p < 0.001.
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As shown in Figure  6A, cells differentiated from human 
CD14+ monocytes to macrophages in the presence of GM-CSF 
had a classical adherent “fried egg” morphology, characteristic 
of classically activated M1 pro-inflammatory macrophages 
(50). Macrophage phenotype was confirmed by testing surface 
antigens by flow cytometry. Monocyte-derived macrophages 
expressed higher levels of HLA-DR and CD14 than undifferenti-
ated monocytes (51). In addition, expression of CD54 (ICAM-1) 
was diminished in comparison with freshly isolated monocytes 
(Figure  6B). CD11a (LFA-1) expression did not change. As 
shown in Figure 6C, adhesion of human monocytes (Figure 6C, 
top) and macrophages (Figure  6C, bottom) was completely 
inhibited by human ICAM-1 confirming that macrophages 
adhere to plastic by LFA-1. As control, lovastatin was able to 
block completely cell adhesion demonstrating that inhibition 
of LFA-1 is sufficient to block macrophage adhesion. It should 
be noted here that other integrins like Mac-1 or VLA-4 are not 
inhibited by lovastatin (43).
In spite of the elevated expression of ICAM-1 in fresh mono-
cytes in comparison with macrophages, it did not correlate 
with the adhesion abilities of both cells (data not shown). As 
indicated previously, since we have used an ICAM-1 form con-
sisting of D1 and D2, we can disregard that ICAM-1 is preventing 
macrophage cell adhesion by blocking Mac-1 that is also known 
to be involved in macrophage cell adhesion (52, 53).
After confirming that human ICAM-1 inhibits adhesion of 
human macrophages by binding to LFA-1, the same test was 
carried out with mouse macrophages in order to support that 
human ICAM-1 is able to functionally bind to mouse LFA-1. 
Differentiation of mouse bone marrow cells to macrophages 
with M-CSF was morphologically (Figure 7A) and phenotypi-
cally (Figure 7B) confirmed. As shown in Figure 7B, these cells 
exhibited a characteristic phenotype of macrophages (CD11b+/
CD11c−) (37). Again, D1D2 and D1D2Fc were able to inhibit the 
adhesion of mouse macrophages although less efficiently than 
in the case of human macrophages (Figure 7C). Lovastatin, an 
inhibitor of LFA-1, was able to completely inhibit the adhesion 
of these cells demonstrating that LFA-1 is the main molecule 
involved in macrophage adhesion also in the mouse system.
In this experimental model, uncoated plastic plates were used 
to analyze if human ICAM-1 was able to bind to mouse LFA-1 
and, thus, interfere with macrophage attachment. However, in 
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